SIR-T GPRC5D

SIR-T GPRC5D is an experimental cell therapy being developed by Angeles Therapeutics for the treatment of GPRC5D-positive malignancies, primarily multiple myeloma. The therapy utilizes the company's proprietary Synthetic Intramembrane Receptor (SIR-T) platform, which involves engineering T cells to express a synthetic receptor designed to recognize and attack cells expressing G protein-coupled receptor class C group 5 member D (GPRC5D). The SIR-T architecture is intended to provide a different signaling mechanism compared to traditional chimeric antigen receptors (CARs), potentially mimicking natural T-cell activation more closely. The program is currently in the discovery phase.